What is the management of resected cholangiocarcinoma in terms of intra- and postoperative status of tumor margins and lymph nodes? A current view.

Schlick, K; Neumayer, B; Neureiter, D. Expert Rev Gastroenterol Hepatol. 2022 Nov-Dec;16(11-12):1019-1022. doi: 10.1080/17474124.2022.2155633. Epub 2022 Dec 13.

Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma – MORSECRC

Gerger, A; Eisterer, W; Fuxius, S; Bastian, S; Koeberle, D; Welslau, M; Sa-noyan, DA; Maas, C; Uhlig, J; Fenchel, K; Greil, R; von der Heyde, E; Agocs, GR; Weide, R; Schwager, M; Reichenbach, F; Modest, DP; Fritsch, R. Anticancer Res. 2022 Oct;42(10):4773-4785. doi: 10.21873/anticanres.15982.

ESMO 2021-highlights in colorectal cancer.

Weiss, L. Memo. 2022;15(2):114-116. doi: 10.1007/s12254-022-00808-7. Epub 2022 Apr 28.

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial.

Moreno, C; Greil, R; Demirkan, F; Tedeschi, A; Anz, B; Larratt, L; Simkovic, M; Novak, J; Strugov, V; Gill, D; Gribben, JG; Kwei, K; Dai, S; Hsu, E; Dean, JP; Flinn, IW. Haematologica.2022 Sep 1;107(9):2108-2120. doi: 10.3324/haematol.2021.279012.

Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study.

Diel, IJ; Greil, R; Janssen, J; Kluike, CW; Behera, B; Abbasi, A; Seesaghur, A; Kellner, M; Jaeger, C; Bjorklof, K; Tomova, A; Haslbauer, F. Support Care Cancer. 2022 Nov;30(11):9267-9278. doi: 10.1007/s00520-022-07333-7. Epub 2022 Sep 6.

DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.

Starzer, AM; Heller, G; Tomasich, E; Melchardt, T; Feldmann, K; Hatziioan-nou, T; Traint, S; Minichsdorfer, C; Schwarz-Nemec, U; Nackenhorst, M; Mul-lauer, L; Preusser, M; Berghoff, AS; Fuereder, T. J Immunother Cancer. 2022 Mar;10(3):e003420. doi: 10.1136/jitc-2021-003420.

Polatuzumab bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.

Tam, CS; Brown, JR; Kahl, BS; Ghia, P; Giannopoulos, K; Jurczak, W; Simko-vic, M; Shadman, M; Osterborg, A; Laurenti, L; Walker, P; Opat, S; Chan, HR; Ciepluch, H; Greil, R; Tani, M; Trneny, M; Brander, DM; Flinn, IW; Grosicki, S; Verner, E; Tedeschi, A; Li, JY; Tian, T; Zhou, L; Marimpietri, C; Paik, JC; Co-hen, A; Huang, JN; Robak, T; Hillmen, P. Lancet Oncol. 2022 Aug;23(8):1031-1043. doi: 10.1016/S1470-2045(22)00293-5. Epub 2022 Jul 7.

Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18.

Minichsdorfer, C; Fuereder, T; Leutner, M; Singer, CF; Kacerovsky-Strobl, S; Egle, D; Greil, R; Balic, M; Fitzal, F; Pfeiler, G; Frantal, S; Bartsch, R; Gnant, M. ESMO Open. 2022 Apr;7(2):100426. doi: 10.1016/j.esmoop.2022.100426. Epub 2022 Mar 22.

Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.

Singer, CF; Holst, F; Steurer, S; Burandt, EC; Lax, SF; Jakesz, R; Rudas, M; Stoger, H; Greil, R; Sauter, G; Filipits, M; Simon, R; Gnant, M; Abcsg, ABCSG. Clin Cancer Res. 2022 Sep 15;28(18):4112-4120. doi: 10.1158/1078-0432.CCR-21-4328.

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.

Nowakowski, GS; Yoon, DH; Peters, A; Mondello, P; Joffe, E; Fleury, I; Greil, R; Ku, M; Marks, R; Kim, K; Zinzani, PL; Trotman, J; Huang, D; Waltl, EE; Winderlich, M; Kurukulasuriya, NC; Ambarkhane, S; Hess, G; Salles, G. Clin Cancer Res. 2022 Sep 15;28(18):4003-4017. doi: 10.1158/1078-0432.CCR-21-3648.